Table 1

Baseline characteristics of the Systemic Lupus International Collaborating Clinics cohort at entry to the study

Number of patients1722
Age, years35.0 (S.D. 13.4)
Gender
 Female1536 (89.2)
 Male186 (10.8)
Enrolment location
 Canada398 (23.1)
 USA497 (28.9)
 Mexico212 (12.3)
 Europe446 (25.9)
 Asia169 (9.8)
Race/ethnicity
 Caucasian830 (48.2)
 Hispanic268 (15.6)
 Asian271 (15.7)
 African origin280 (16.3)
 Other71 (4.1)
Disease phenotype at baseline
 SLEDAI-2K5.3 (5.3)*
 Active renal disease467 (27.1)
 Thrombocytopenia (platelet count <100 000)47 (2.7)
Medication use
 Oral corticosteroids (CS)1199 (69.6)
 Average CS dose (mg/day)24.1 (16.7)*
 Highest CS dose (mg/day)43.5 (74.3)*
 Immunosuppressants684 (39.7)
 Antimalarials1153 (67)
Co-morbidities
 Systolic blood pressure (mm Hg)119.5 (16.8)*
 Diastolic blood pressure (mm Hg)75.1 (11.1)*
 Taking antihypertensives505 (29.3)
 Diabetes mellitus60 (3.5)
 Current smoker263 (15.3)
 Post-menopausal162 (9.4)
 Body mass index (kg/m2)25.2 (5.9)*
Baseline serology
 Anti-dsDNA positive663 (38.5)
 Low C3 and/or C4 complement586 (34.0)
 Anti-B2-GPI positive241 (14)
 Anti-cardiolipin positive133 (7.7)
 Lupus anticoagulant positive208 (12.1)
  • *All data are n (%) of patients or mean (SD) where indicated.

  • SLEDAI-2K, Systemic Lupus Erythematosus Disease Activity Index 2000.